Lack of c-erbB-2 oncoprotein expression in male breast carcinoma.
Open Access
- 1 November 1991
- journal article
- research article
- Published by BMJ in Journal of Clinical Pathology
- Vol. 44 (11) , 960-961
- https://doi.org/10.1136/jcp.44.11.960
Abstract
A series of 21 male breast carcinomas were immunostained using NCL-CB11, an antibody directed against the internal domain of the c-erbB-2 transmembrane oncoprotein. In contrast to female breast cancer, where up to 35% of cases show positivity, all of these cases were negative. This suggests that no prognostic information regarding patient survival can be made in these patients and that male breast carcinomas may be under different growth control mechanisms from female breast carcinomas.Keywords
This publication has 8 references indexed in Scilit:
- c‐erbB‐2 oncoprotein expression in mammary and extramammary Paget's disease: an immunohistochemical studyHistopathology, 1990
- neu oncogene protein and epidermal growth factor receptor are independently expressed in benign and malignant breast tissuesHuman Pathology, 1990
- NCL‐CB11, a new monoclonal antibody recognizing the internal domain of the c‐erbB‐2 oncogene protein effective for use on formalin‐fixed, paraffin‐embedded tissueThe Journal of Pathology, 1990
- AMPLIFICATION OF THE C-ERB B-2 ONCOGENE AND PROGNOSIS OF BREAST ADENOCARCINOMA1990
- c-erbB-2 oncoprotein expression in primary human tumorsCancer, 1990
- Endocrine epidemiology of male breast cancer (review).1988
- The Endocrinology of the Abnormal Male BreastAnnals of the New York Academy of Sciences, 1986